X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (90) 90
index medicus (85) 85
male (72) 72
middle aged (62) 62
female (57) 57
aged (56) 56
adult (49) 49
prognosis (37) 37
immunoblastic lymphadenopathy - pathology (36) 36
immunoblastic lymphadenopathy - mortality (35) 35
hematology (34) 34
immunoblastic lymphadenopathy - diagnosis (25) 25
immunoblastic lymphadenopathy - drug therapy (25) 25
lymphoma, t-cell - mortality (23) 23
oncology (23) 23
aged, 80 and over (22) 22
antineoplastic combined chemotherapy protocols - therapeutic use (20) 20
immunoblastic lymphadenopathy - complications (20) 20
angioimmunoblastic t-cell lymphoma (18) 18
lymph nodes - pathology (18) 18
abridged index medicus (17) 17
immunoblastic lymphadenopathy - therapy (17) 17
retrospective studies (16) 16
lymphoma, t-cell - pathology (15) 15
lymphadenopathy (14) 14
lymphoma (14) 14
lymphomas (14) 14
survival analysis (14) 14
t cells (14) 14
non-hodgkins-lymphoma (13) 13
survival (13) 13
survival rate (13) 13
treatment outcome (13) 13
adolescent (12) 12
chemotherapy (11) 11
diagnosis, differential (11) 11
dysproteinemia (11) 11
lymphoma, t-cell - drug therapy (11) 11
neoplasm staging (11) 11
remission induction (11) 11
cancer (10) 10
lymphoma, t-cell - diagnosis (10) 10
non-hodgkin's lymphomas (10) 10
therapy (10) 10
angio-immunoblastic lymphadenopathy (9) 9
cyclophosphamide - therapeutic use (9) 9
disease progression (9) 9
epstein-barr-virus (9) 9
expression (9) 9
immunoblastic lymphadenopathy (9) 9
immunoblastic lymphadenopathy - immunology (9) 9
lymphoproliferative disorders (9) 9
pathology (9) 9
peripheral t-cell lymphoma (9) 9
t-cell lymphoma (9) 9
vincristine - therapeutic use (9) 9
doxorubicin - therapeutic use (8) 8
lymphoma, t-cell - therapy (8) 8
lymphoma, t-cell, peripheral - diagnosis (8) 8
lymphoma, t-cell, peripheral - mortality (8) 8
prednisone - therapeutic use (8) 8
transplantation (8) 8
child (7) 7
disease-free survival (7) 7
kaplan-meier estimate (7) 7
non-hodgkins-lymphomas (7) 7
risk factors (7) 7
angioimmunoblastic lymphadenopathy (6) 6
antineoplastic agents - therapeutic use (6) 6
epstein-barr virus (6) 6
features (6) 6
immunoblastic lymphadenopathy - genetics (6) 6
lymphoma - pathology (6) 6
lymphoma, t-cell - complications (6) 6
lymphoma, t-cell - genetics (6) 6
patients (6) 6
proportional hazards models (6) 6
stem cell transplantation (6) 6
classification (5) 5
cyclophosphamide - administration & dosage (5) 5
fatal outcome (5) 5
follow-up studies (5) 5
helper-cells (5) 5
hematopoietic stem cell transplantation (5) 5
hemic and lymphatic diseases (5) 5
immunophenotyping (5) 5
lymphocytes t (5) 5
lymphoma, t-cell, peripheral - pathology (5) 5
lymphoma, t-cell, peripheral - therapy (5) 5
medicine (5) 5
medicine & public health (5) 5
patient outcomes (5) 5
t-lymphocytes - immunology (5) 5
treatment (5) 5
aids/hiv (4) 4
aitl (4) 4
analysis (4) 4
animals (4) 4
child, preschool (4) 4
combined modality therapy (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Haematology, ISSN 0007-1048, 03/2017, Volume 176, Issue 5, pp. 750 - 758
Journal Article
Journal Article
Haematologica, ISSN 0390-6078, 10/2012, Volume 97, Issue 10, pp. 1594 - 1602
Background In angioimmunoblastic T-cell lymphoma, symptoms linked to B-lymphocyte activation are common, and variable numbers of CD20(+) large B-blasts, often... 
Angioimmunoblastic t-cell lymphoma | Epstein-barr virus | Chop-r | VIRAL LOAD | MULTICENTER | angioimmunoblastic T-cell lymphoma | FOLLICULAR HELPER-CELL | NON-HODGKINS-LYMPHOMAS | PERIPHERAL-BLOOD | REARRANGEMENTS | PREDNISONE | POLYMERASE-CHAIN-REACTION | Epstein-Barr virus | CHOP-R | HEMATOLOGY | EXPRESSION | EPSTEIN-BARR-VIRUS | Doxorubicin - therapeutic use | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Immunoblastic Lymphadenopathy - mortality | B-Lymphocytes - virology | Female | Immunoblastic Lymphadenopathy - pathology | B-Lymphocytes - pathology | Prednisone - adverse effects | Rituximab | Immunoblastic Lymphadenopathy - drug therapy | Treatment Outcome | B-Lymphocytes - drug effects | Lymphoma, T-Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, T-Cell - pathology | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Lymphoma, T-Cell - mortality | Antibodies, Monoclonal, Murine-Derived - pharmacology | Neoplasm Staging | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Index Medicus | Original and Brief Reports
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 09/2014, Volume 55, Issue 9, pp. 2038 - 2047
Journal Article
Cell Cycle, ISSN 1538-4101, 06/2016, Volume 15, Issue 12, pp. 1545 - 1551
Journal Article
Journal Article
Modern Pathology, ISSN 0893-3952, 06/2012, Volume 25, Issue 6, pp. 805 - 814
The angiogenic microenvironment has been known to be a component of angioimmunoblastic T-cell lymphoma since its initial characterization. We have shown that... 
BCL2 | angioimmunoblastic T-cell lyphoma | CD105 | endothelial cell | neoangiogenesis | VEGF | SURVIVAL | BREAST-CARCINOMA | ANGIOGENESIS | SOLID HUMAN TUMORS | PATHOLOGY | INTERNATIONAL CONSENSUS | ENDOTHELIAL-CELLS | GROWTH | BLOOD-VESSELS | NON-HODGKINS-LYMPHOMA | ENDOGLIN CD105 | Antigens, CD34 - analysis | Humans | Middle Aged | Microvessels - pathology | Tumor Microenvironment | Male | Vascular Endothelial Growth Factor A - genetics | Antigens, CD - analysis | Time Factors | Aged, 80 and over | Immunoblastic Lymphadenopathy - pathology | Real-Time Polymerase Chain Reaction | Endothelial Cells - chemistry | Lymph Nodes - chemistry | Risk Assessment | Risk Factors | Lymph Nodes - immunology | Disease Progression | Immunoblastic Lymphadenopathy - therapy | Lymphoma, T-Cell - therapy | Biomarkers, Tumor - genetics | Endothelial Cells - pathology | Microvessels - chemistry | Immunoblastic Lymphadenopathy - metabolism | Multivariate Analysis | Lymphoma, T-Cell - immunology | Lymph Nodes - pathology | Receptors, Cell Surface - analysis | Neovascularization, Pathologic | Laser Capture Microdissection | RNA, Messenger - analysis | Microvessels - immunology | Case-Control Studies | Endoglin | Lymphoma, T-Cell - chemistry | Immunoblastic Lymphadenopathy - mortality | Lymph Nodes - blood supply | Proto-Oncogene Proteins c-bcl-2 - analysis | Adult | Female | Biomarkers, Tumor - analysis | Immunoblastic Lymphadenopathy - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Vascular Endothelial Growth Factor A - analysis | Chi-Square Distribution | Lymphoma, T-Cell - genetics | Endothelial Cells - immunology | Disease-Free Survival | Fluorescent Antibody Technique | Lymphoma, T-Cell - pathology | Aged | Lymphoma, T-Cell - mortality | Immunoblastic Lymphadenopathy - immunology | Proto-Oncogene Proteins c-bcl-2 - genetics | Paris | Index Medicus | CD34 antigen | Tumor cells | Hyperplasia | Gene expression | Endothelial cells | Lymph nodes | Polymerase chain reaction | Angiogenesis | Bone marrow | Microenvironments | Immunofluorescence | T-cell lymphoma | CD105 antigen | Tumors | squamous cell carcinoma | Life Sciences | Cancer | Antigens, CD34 | Vascular Endothelial Growth Factor A | Endothelial Cells | pathology | Lymphoma, T-Cell | Receptors, Cell Surface | Angioimmunolbastic T-Cell Lyphoma, BCL2, CD105, endothelial cell, neoangiogenesis, VEGF | genetics | Microvessels | immunology | chemistry | Tumor Markers, Biological | Immunoblastic Lymphadenopathy | therapy | analysis | Lymph Nodes | blood supply | mortality | metabolism | Proto-Oncogene Proteins c-bcl-2 | RNA, Messenger | Antigens, CD
Journal Article
Journal Article
Haematologica, ISSN 0390-6078, 11/2003, Volume 88, Issue 11, pp. 1272 - 1278
Journal Article
Journal Article